A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs BGB 290 (Primary) ; Temozolomide (Primary)
- Indications Advanced breast cancer; Gastric cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer
- Focus Adverse reactions
- Sponsors BeiGene
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 30 Aug 2017 According to a BeiGene media release, results from this trial will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
- 09 Aug 2017 Status changed from not yet recruiting to recruiting.